Skylar Jeremias

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change for children with the disease.

Roundtable reveals vitiligo care gaps: Opzelura leads, insurers still call it cosmetic, and pricey oral JAKs near approval—what’s next?

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

At an AJMC roundtable, Atlanta clinicians detailed blood-based biomarker gaps, uncompensated care, and capacity strains slowing Alzheimer diagnosis.

Clinicians at a Chicago panel say atopic dermatitis biologic therapy is delayed by specialty pharmacy access, prior authorization, co-pay maximizer plans, and topical steroid underuse.

Basement membrane composition actively drives NSCLC invasion, metastasis, and treatment resistance, a review finds, rather than serving as passive scaffolding.

Chronic hand eczema affects roughly 5% of adults each year, exacts most of its toll at work, and is not simply atopic dermatitis of the hands.

A Canadian expert panel says SALT scores miss the point: its new algorithm weighs quality of life and disease pace to guide alopecia areata treatment.

The AACR roadmap spotlights LDCT screening, ctDNA MRD monitoring, and new NSCLC/SCLC therapies like DLL3 tarlatamab to close survival gaps.